210 related articles for article (PubMed ID: 9767232)
1. Expression of CD95 ligand in melanocytic lesions as a diagnostic marker.
Maeda A; Aragane Y; Tezuka T
Br J Dermatol; 1998 Aug; 139(2):198-206. PubMed ID: 9767232
[TBL] [Abstract][Full Text] [Related]
2. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
3. A case of acral lentginous melanoma: the correlation between CD95L expression on melanoma cells and apoptosis of tumor infiltrating lymphocytes.
Maeda A; Aragane Y; Kawada A; Isogai R; Orita T; Tezuka T
J Dermatol; 2001 Sep; 28(9):499-504. PubMed ID: 11603392
[TBL] [Abstract][Full Text] [Related]
4. [Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions].
Lampert A; Thomine E; Lauret P; Hemet J
Ann Pathol; 1993; 13(2):100-7. PubMed ID: 8363667
[TBL] [Abstract][Full Text] [Related]
5. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
[TBL] [Abstract][Full Text] [Related]
6. Frequent downregulation of Fas (CD95) expression and function in melanoma.
Bullani RR; Wehrli P; Viard-Leveugle I; Rimoldi D; Cerottini JC; Saurat JH; Tschopp J; French LE
Melanoma Res; 2002 Jun; 12(3):263-70. PubMed ID: 12140383
[TBL] [Abstract][Full Text] [Related]
7. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
Fröhlich E; Mack AF; Garbe C; Klessen C
Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
[TBL] [Abstract][Full Text] [Related]
8. Micro-anatomy related antigen expression in melanocytic lesions.
Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of Fas and Fas-ligand expression during melanoma progression.
Soubrane C; Mouawad R; Antoine EC; Verola O; Gil-Delgado M; Khayat D
Br J Dermatol; 2000 Aug; 143(2):307-12. PubMed ID: 10951137
[TBL] [Abstract][Full Text] [Related]
10. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
[TBL] [Abstract][Full Text] [Related]
11. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival.
Neuber K; Eidam B
Onkologie; 2006 Sep; 29(8-9):361-5. PubMed ID: 16974112
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of combining PRAME and HMB-45 stains in primary melanocytic tumors.
Rasic D; Korsgaard N; Marcussen N; Precht Jensen EM
Ann Diagn Pathol; 2023 Dec; 67():152211. PubMed ID: 37717457
[TBL] [Abstract][Full Text] [Related]
13. The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions.
Kuźbicki Ł; Lange D; Strączyńska-Niemiec A; Chwirot BW
Melanoma Res; 2012 Feb; 22(1):70-6. PubMed ID: 22228276
[TBL] [Abstract][Full Text] [Related]
14. Moesin and CD44 expression in cutaneous melanocytic tumours.
Ichikawa T; Masumoto J; Kaneko M; Saida T; Sagara J; Taniguchi S
Br J Dermatol; 1998 May; 138(5):763-8. PubMed ID: 9666819
[TBL] [Abstract][Full Text] [Related]
15. Association of vascular endothelial growth factor expression with patohistological parameters of cutaneous melanoma.
Gacević M; Jović M; Zolotarevski L; Stanojević I; Novaković M; Miller K; Šuljagić V; Mijušković Ž; Vojvodić D
Vojnosanit Pregl; 2016 May; 73(5):449-57. PubMed ID: 27430109
[TBL] [Abstract][Full Text] [Related]
16. [Dysplastic nevus in differential epiluminescence microscopy diagnosis of melanoma].
Schulz H
Hautarzt; 1996 Feb; 47(2):109-13. PubMed ID: 8868454
[TBL] [Abstract][Full Text] [Related]
17. The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers.
Quiohilag K; Caie P; Oniscu A; Brenn T; Harrison D
Virchows Arch; 2020 Jul; 477(1):121-130. PubMed ID: 32388720
[TBL] [Abstract][Full Text] [Related]
18. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours.
Sanders DS; Blessing K; Hassan GA; Bruton R; Marsden JR; Jankowski J
Mol Pathol; 1999 Jun; 52(3):151-7. PubMed ID: 10621837
[TBL] [Abstract][Full Text] [Related]
19. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas.
Glaessl A; Bosserhoff AK; Buettner R; Hohenleutner U; Landthaler M; Stolz W
Arch Dermatol Res; 1999; 291(2-3):81-7. PubMed ID: 10195394
[TBL] [Abstract][Full Text] [Related]
20. The ultrastructure of dysplastic naevi: comparison with superficial spreading melanoma and common naevocellular naevi.
Langer K; Rappersberger K; Steiner A; Konrad K; Wolff K
Arch Dermatol Res; 1990; 282(6):353-62. PubMed ID: 2260880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
